Assessment of diagnostic accuracy of Gazelle: A point-of-care testing device for screening β-thalassemia trait
The Indian Journal of Medical Research · 2024
DOI: 10.25259/ijmr_1986_23 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift The Indian Journal of Medical Research, 2024. Verfasst von Neha Singh und 2 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Community Medicine, All India Institute of Medical Science, New Delhi, India. Hauptthemen laut MEDLINE: beta-Thalassemia, Ferritins, Point-of-Care Testing. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background & objectives Timely detection of population with β-thalassemia trait (BTT) followed by genetic counselling is an advocated method of preventing the birth of a child with β-thalassemia major. In this study we aim to assess the diagnostic accuracy of Gazelle, a point-of-care (POC) testing device, in screening for BTT in hospital laboratory setting.
Methods
Standards for Reporting Diagnostic Accuracy (STARD) guidelines were followed in developing study design, recruiting study participants and sample size calculation for the current research. A consecutive sample of 446 participants was recruited for this study and was tested for the reference test Gazelle as well as the gold standard cation exchange high performance liquid chromatography (CE-HPLC). Low serum ferritin levels are known to interfere with the production of HbA2 and in turn lead to false negative results. Hence, the study population was divided into two categories with respect to a cut off value of 15ng/dl of serum ferritin and the results were analyzed.
Results
Overall diagnostic accuracy of Gazelle for detecting BTT was found to be 95.3 per cent with a confidence interval (CI) of (92.9 - 97.1) and the sensitivity was 94.5 per cent with a 95% CI of (84.8 - 98.8). When analyzed by the serum ferritin level the diagnostic accuracy was found to be 94.7 per cent (91.1% - 97.1%) and 95.7 per cent (91.8% - 98.1%) for participants with serum ferritin level as > 15 ng/ml and < 15 ng/ml, respectively. Interpretation & conclusions This study found Gazelle to be a good screening tool for β-thalassemia trait with high sensitivity, specificity and accuracy. However, it is recommended that the final confirmation of the diagnosis done by a diagnostic test like HPLC or Capillary Zone Electrophoresis (CZE).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre for Community Medicine, All India Institute of Medical Science, New Delhi, India.
- Department of Haematology, All India Institute of Medical Science, New Delhi, India.
Zitieren
APA
Singh, N., Seth, T., & Dass, J. (2024). Assessment of diagnostic accuracy of Gazelle: A point-of-care testing device for screening β-thalassemia trait. The Indian Journal of Medical Research. https://doi.org/10.25259/ijmr_1986_23
Vancouver
Singh N, Seth T, Dass J. Assessment of diagnostic accuracy of Gazelle: A point-of-care testing device for screening β-thalassemia trait. The Indian Journal of Medical Research. 2024. doi:10.25259/ijmr_1986_23
BibTeX
@article{Singh2024,
author = {Singh, Neha and Seth, Tulika and Dass, Jasmita},
title = {Assessment of diagnostic accuracy of Gazelle: A point-of-care testing device for screening β-thalassemia trait},
journal = {The Indian Journal of Medical Research},
year = {2024},
doi = {10.25259/ijmr_1986_23}
}
EUVIMED